ReviewClinical research in cardiology : official journal of the German Cardiac Society2021
Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).
Review in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Machine learning-based methods in diagnosing cardiac amyloidosis: a meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- A systematic review for the evidence of recommendations and guidelines in hybrid nuclear cardiovascular imaging.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.Archivos de cardiologia de Mexico · 2024Guideline
- Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.European journal of heart failure · 2022Pooled it
- Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.ESC heart failure · 2022Pooled it
- Optimizing Diagnosis of Transthyretin Amyloidosis Cardiomyopathy in Japan: Care Pathway Barriers and Opportunities.Circulation reports · 2026Article
- Unraveling cardiac amyloidosis in Egypt: diagnostic challenges and disease outcomes.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Cardiac Amyloidosis: Pathogenesis, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2026Review
- Semi-quantitative evaluation of early phaseAnnals of nuclear medicine · 2026Article
- Cardiac magnetic resonance T1 mapping for amyloid cardiomyopathy in patients with heart failure.European heart journal. Imaging methods and practice · 2026Article
- CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Observational
- QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Multimodal Imaging for Monitoring of Disease Progression in Cardiac Amyloidosis: Advances and Gaps in Evidence.Journal of cardiovascular development and disease · 2026Review
- Cardiac amyloidosis: From diagnosis to therapeutics breakthroughs.World journal of experimental medicine · 2026Review
- Cardiac imaging in hypertrophic cardiomyopathy and cardiac amyloidosis: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags.Scientific reports · 2025Article
- Assessing the quality of reporting in artificial intelligence/machine learning research for cardiac amyloidosis.JAMIA open · 2025Article
- Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.The international journal of cardiovascular imaging · 2025Review
- Myocardial Perfusion Imaging with Cardiovascular Magnetic Resonance in Nonischemic Cardiomyopathies: An In-Depth Review of Techniques and Clinical Applications.Medicina (Kaunas, Lithuania) · 2025Review
- Depressive symptoms delayed but subsequently led to the diagnosis of transthyretin amyloidosis: a case report.The Journal of international medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic forms of amyloidosis affecting the heart are mostly light-chain (AL) and transthyretin (ATTR) amyloidoses. The latter is caused by deposition of misfolded transthyretin, either in wild-type (ATTRwt) or mutant (ATTRv) conformation. For diagnostics, specific serum biomarkers and modern non-invasive imaging techniques, such as cardiovascular magnetic resonance imaging (CMR) and scintigraphic methods, are available today. These imaging techniques do not only complement conventional echocardiography, but also allow for accurate assessment of the extent of cardiac involvement, in addition to diagnosing cardiac amyloidosis. Endomyocardial biopsy still plays a major role in the histopathological diagnosis and subtyping of cardiac amyloidosis. The main objective of the diagnostic algorithm outlined in this position statement is to detect cardiac amyloidosis as reliably and early as possible, to accurately determine its extent, and to reliably identify the underlying subtype of amyloidosis, thereby enabling subsequent targeted treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.